Talkin’ Toxins: From Coley’s to Modern Cancer Immunotherapy

FDA Approval Summary: Atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1

(2020) Preeti Narayan et al.   CLINICAL CANCER RESEARCH

Triassic Cancer—Osteosarcoma in a 240-Million-Year-Old Stem-Turtle

(2019) Yara Haridy et al.   JAMA Oncology

Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer

(2019) Winifred Lo et al.   Cancer Immunology Research

Regulatory T cells in cancer immunosuppression — implications for anticancer therapy

(2019) Yosuke Togashi et al.   Nature Reviews Clinical Oncology

Genomics-Guided Immunotherapy for Precision Medicine in Cancer

(2019) Shradha Mukherjee   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Tumor neoantigens: from basic research to clinical applications

(2019) Tao Jiang et al.   Journal of Hematology & Oncology

Neoantigen vaccine: an emerging tumor immunotherapy

(2019) Miao Peng et al.   Molecular Cancer

Comparison of DNA and mRNA vaccines against cancer

(2019) Zohreh Jahanafrooz et al.   DRUG DISCOVERY TODAY

Cervical Cancer Incidence in Young U.S. Females After Human Papillomavirus Vaccine Introduction

(2018) Fangjian Guo et al.   AMERICAN JOURNAL OF PREVENTIVE MEDICINE

Mechanisms of resistance to immune checkpoint inhibitors

(2018) Russell W Jenkins et al.   BRITISH JOURNAL OF CANCER

Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors

(2018) Kristian M. Hargadon et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry

(2018) Paul C. Mayor et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

(2018) Thomas Powles et al.   LANCET

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

(2018) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives

(2018) Remy Thomas et al.   Frontiers in Immunology

Hypoxia-Driven Immunosuppressive Metabolites in the Tumor Microenvironment: New Approaches for Combinational Immunotherapy

(2018) Yiliang Li et al.   Frontiers in Immunology

Cytokine release syndrome

(2018) Alexander Shimabukuro-Vornhagen et al.   Journal for ImmunoTherapy of Cancer

Tune Up In Situ Autovaccination against Solid Tumors with Oncolytic Viruses

(2018) Teresa Nguyen et al.   Cancers

Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors

(2018) Trevor R. Baybutt et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

(2018) Derin B. Keskin et al.   NATURE

Adoptive cell therapy: past, present and future

(2017) Jonathan E Cohen et al.   Immunotherapy

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

(2017) Jacob Schachter et al.   LANCET

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study

(2017) Smita S Chandran et al.   LANCET ONCOLOGY

An immunogenic personal neoantigen vaccine for patients with melanoma

(2017) Patrick A. Ott et al.   NATURE

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

(2017) V. Gopalakrishnan et al.   SCIENCE

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

(2017) Bertrand Routy et al.   SCIENCE

Cytokines in Cancer Immunotherapy

(2017) Thomas A. Waldmann   Cold Spring Harbor Perspectives in Biology

Oncolytic Viruses in Cancer Treatment

(2017) Sean E. Lawler et al.   JAMA Oncology

Immunotherapy and tumor microenvironment

(2016) Haidong Tang et al.   CANCER LETTERS

The urgent need to recover MHC class I in cancers for effective immunotherapy

(2016) Federico Garrido et al.   CURRENT OPINION IN IMMUNOLOGY

Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation

(2016) Ana C. Anderson et al.   IMMUNITY

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

(2016) Howard L Kaufman et al.   LANCET ONCOLOGY

Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Cancer Research Group (E4697)

(2015) David H. Lawson et al.   JOURNAL OF CLINICAL ONCOLOGY

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

(2015) James N. Kochenderfer et al.   JOURNAL OF CLINICAL ONCOLOGY

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

(2015) Dirk Schadendorf et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

(2015) Jeffrey S Weber et al.   LANCET ONCOLOGY

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adoptive cell transfer as personalized immunotherapy for human cancer

(2015) S. A. Rosenberg et al.   SCIENCE

Going viral: a review of replication-selective oncolytic adenoviruses

(2015) Christopher Larson et al.   Oncotarget

Antibody-modified T cells: CARs take the front seat for hematologic malignancies

(2014) M. V. Maus et al.   BLOOD

Current concepts in the diagnosis and management of cytokine release syndrome

(2014) D. W. Lee et al.   BLOOD

Mechanisms of Hypoxia-Mediated Immune Escape in Cancer

(2014) I. B. Barsoum et al.   CANCER RESEARCH

Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma

(2014) F. Stephen Hodi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer

(2014) E. Tran et al.   SCIENCE

Immunotherapy for Prostate Cancer: Lessons from Responses to Tumor-Associated Antigens

(2014) Harm Westdorp et al.   Frontiers in Immunology

Salmonellaas a vaccine delivery vehicle

(2013) Kenneth L Roland et al.   Expert Review of Vaccines

Dendritic-Cell-Based Therapeutic Cancer Vaccines

(2013) Karolina Palucka et al.   IMMUNITY

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

(2013) Paul F Robbins et al.   NATURE MEDICINE

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines

(2013) A Q Butt et al.   ONCOGENE

Cancer Immunotherapy

(2013) J. Couzin-Frankel   SCIENCE

MUC1 Vaccine for Individuals with Advanced Adenoma of the Colon: A Cancer Immunoprevention Feasibility Study

(2012) T. Kimura et al.   Cancer Prevention Research

Poxviral vectors for cancer immunotherapy

(2012) Joseph W Kim et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Expression of tumour-specific antigens underlies cancer immunoediting

(2012) Michel DuPage et al.   NATURE

NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors

(2012) Christopher A Alvarez-Breckenridge et al.   NATURE MEDICINE

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Carcinoembryonic Antigen (CEA)-Based Cancer Vaccines: Recent Patents and Antitumor Effects from Experimental Models to Clinical Trials

(2012) Mario Turriziani et al.   Recent Patents on Anti-Cancer Drug Discovery

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

(2011) J. N. Kochenderfer et al.   BLOOD

Spectrum of Cancer Risk Among US Solid Organ Transplant Recipients

(2011) Eric A. Engels et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

(2011) Paul F. Robbins et al.   JOURNAL OF CLINICAL ONCOLOGY

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4

(2011) O. S. Qureshi et al.   SCIENCE

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

(2011) M. Kalos et al.   Science Translational Medicine

Cytokines in Cancer Immunotherapy

(2011) Sylvia Lee et al.   Cancers

Single, double and triple alanine to glycine replacements in the AxAxAxA motif of alkaliphilic Bacillus pseudofirmus OF4 c-subunits affect c-ring stability, change both monomer and c-ring mobility in SDS-PAGE and lead to deficits in ATP synthesis

(2010) Jun Liu et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

(2010) J. N. Kochenderfer et al.   BLOOD

Accumulation of Foxp3+ T Regulatory Cells in Draining Lymph Nodes Correlates with Disease Progression and Immune Suppression in Colorectal Cancer Patients

(2010) L. Deng et al.   CLINICAL CANCER RESEARCH

T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis

(2010) Maria R Parkhurst et al.   MOLECULAR THERAPY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

(2009) L. A. Johnson et al.   BLOOD

The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease

(2009) T. R. Hercus et al.   BLOOD

The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research

(2009) M. A. Cheever et al.   CLINICAL CANCER RESEARCH

Phase II Multicenter Trial of Maintenance Biotherapy After Induction Concurrent Biochemotherapy for Patients With Metastatic Melanoma

(2009) Steven J. O'Day et al.   JOURNAL OF CLINICAL ONCOLOGY

Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy

(2009) Daniel Hollyman et al.   JOURNAL OF IMMUNOTHERAPY

High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor   fusion protein, in metastatic melanoma and colorectal cancer

(2009) A. Bessard et al.   MOLECULAR CANCER THERAPEUTICS

Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo

(2009) Michael C. Milone et al.   MOLECULAR THERAPY

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

(2008) B. G. Till et al.   BLOOD

Regulatory T Cells and Immune Tolerance

(2008) Shimon Sakaguchi et al.   CELL

α-Fetoprotein and other tumour-associated antigens for immunotherapy of hepatocellular cancer

(2008) Viktoria N Evdokimova et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Inflammatory signals in dendritic cell activation and the induction of adaptive immunity

(2008) Olivier Joffre et al.   IMMUNOLOGICAL REVIEWS

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

(2008) Martin A Pule et al.   NATURE MEDICINE